Telix Pharmaceuticals

Telix Pharmaceuticals Limited (ASX: TLX) is a biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals. Founded in 2015 and headquartered in Melbourne, Australia, Telix has international operations in the US, Europe, and Japan.

Telix's lead product is Illuccix, a gallium-68 labeled gozetotide injection used for prostate cancer imaging. Illuccix was approved by the US Food and Drug Administration (FDA) in December 2021 and is also approved in Australia and Canada. The company's pipeline includes additional radiopharmaceutical candidates for imaging and treating various cancers, including renal, brain, and musculoskeletal cancers.

Telix reported total revenue of AUD 364.0 million for the first half of 2024, a 65% increase compared to the same period in 2023. This growth was primarily driven by sales of Illuccix in the US. The company achieved a net profit after tax of AUD 29.7 million in H1 2024, compared to a net loss of AUD 14.3 million in H1 2023. Telix reaffirmed its full year 2024 revenue guidance of USD 490-510 million.